A cost of illness study of allergic rhinitis in the United States
- PMID: 9003207
- DOI: 10.1016/s0091-6749(97)70296-3
A cost of illness study of allergic rhinitis in the United States
Abstract
Background: Allergic rhinitis is a common condition, but the burden of this condition on the national economy is not well understood.
Objective: The purpose of this study was to estimate the national direct and indirect costs of allergic rhinitis.
Methods: Data from the National Medical Expenditure Survey were used to provide estimates of resource utilization, medical expenditures, and lost productivity. With the complex survey design, variance estimates were used to construct confidence intervals for cost estimates of resource utilization and lost productivity.
Results: It is estimated that approximately 39 million persons in the United States experienced allergic rhinitis in 1987. However, only 12.3% (4.8 million) sought medical treatment for allergic rhinitis. The total estimated cost of the condition, in 1994 dollars, was $1.23 billion (95% confidence interval, $846 million to $1.62 billion). Direct medical expenses accounted for 94% of total costs. Allergic rhinitis results in approximately 811,000 missed workdays, 824,000 missed school days, and 4,230,000 reduced activity days.
Conclusion: Allergic rhinitis clearly creates a burden in terms of the number of persons affected, total expenditures, and lost productivity. It also appears that a relatively large proportion of persons with allergic rhinitis were not seeking medical treatment.
Similar articles
-
The economic burden of allergic rhinitis: a critical evaluation of the literature.Pharmacoeconomics. 2004;22(6):345-61. doi: 10.2165/00019053-200422060-00002. Pharmacoeconomics. 2004. PMID: 15099121 Review.
-
Economic burden of allergic rhinitis in Korea.Am J Rhinol Allergy. 2010 Sep-Oct;24(5):e110-3. doi: 10.2500/ajra.2010.24.3513. Am J Rhinol Allergy. 2010. PMID: 21244726
-
The cost of productivity losses associated with allergic rhinitis.Am J Manag Care. 2000 Mar;6(3):373-8. Am J Manag Care. 2000. PMID: 10977437
-
Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis.Pharmacoeconomics. 2004;22(14):929-42. doi: 10.2165/00019053-200422140-00003. Pharmacoeconomics. 2004. PMID: 15362929
-
[Allergic rhinitis--an epidemiological, economical and social problem of the XXI century].Pneumonol Alergol Pol. 2008;76(5):348-52. Pneumonol Alergol Pol. 2008. PMID: 19003765 Review. Polish.
Cited by
-
Prevention of food and airway allergy: consensus of the Italian Society of Preventive and Social Paediatrics, the Italian Society of Paediatric Allergy and Immunology, and Italian Society of Pediatrics.World Allergy Organ J. 2016 Aug 18;9:28. doi: 10.1186/s40413-016-0111-6. eCollection 2016. World Allergy Organ J. 2016. PMID: 27583103 Free PMC article. Review.
-
The economic burden of allergic rhinitis: a critical evaluation of the literature.Pharmacoeconomics. 2004;22(6):345-61. doi: 10.2165/00019053-200422060-00002. Pharmacoeconomics. 2004. PMID: 15099121 Review.
-
Overview on the pathomechanisms of allergic rhinitis.Asia Pac Allergy. 2011 Oct;1(3):157-67. doi: 10.5415/apallergy.2011.1.3.157. Epub 2011 Oct 11. Asia Pac Allergy. 2011. PMID: 22053313 Free PMC article.
-
Assessment of Patient Attitudes About Mometasone Furoate Nasal Spray: The Ease-of-Use Patient Survey.World Allergy Organ J. 2008 Sep;1(9):156-9. doi: 10.1097/WOX.0b013e3181865f99. World Allergy Organ J. 2008. PMID: 23282579 Free PMC article.
-
Latest developments in the management of allergic rhinitis.Clin Rev Allergy Immunol. 2004 Dec;27(3):181-9. doi: 10.1385/CRIAI:27:3:181. Clin Rev Allergy Immunol. 2004. PMID: 15630154 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources